
Johannes Betge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2178722/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of liverâ€derived bone morphogenetic protein (BMP)â€9 as a potential new candidate for treatment of colorectal cancer. Journal of Cellular and Molecular Medicine, 2022, 26, 343-353.	3.6	3
2	Neglected geriatric assessment and overtreatment of older patients with pancreatic cancer - Results from a prospective phase IV clinical trial. Journal of Geriatric Oncology, 2022, 13, 662-666.	1.0	3
3	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	3.2	23
4	Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial) Journal of Clinical Oncology, 2022, 40, 303-303.	1.6	1
5	Personalized functional profiling using <i>ex-vivo</i> patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid. Cancer Biology and Therapy, 2022, 23, 96-102.	3.4	3
6	Endoscopy capsule in the scrotum. Journal of Gastrointestinal and Liver Diseases, 2022, 31, 147-148.	0.9	0
7	The drug-induced phenotypic landscape of colorectal cancer organoids. Nature Communications, 2022, 13, .	12.8	22
8	Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. The Lancet Healthy Longevity, 2022, 3, e417-e427.	4.6	11
9	Multiâ€omics integration identifies a selective vulnerability of colorectal cancer subtypes to <scp>YM155</scp> . International Journal of Cancer, 2021, 148, 1948-1963.	5.1	11
10	PPARÎ ³ induces PD-L1 expression in MSS+ colorectal cancer cells. OncoImmunology, 2021, 10, 1906500.	4.6	15
11	Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. Cells, 2021, 10, 648.	4.1	47
12	Nivolumab and ipilimumab for second-line therapy in elderly patients with advanced esophageal squamous cell cancer: Safety interim analysis of the RAMONA trial Journal of Clinical Oncology, 2021, 39, 4029-4029.	1.6	2
13	Patient-Derived Organoids of Cholangiocarcinoma. International Journal of Molecular Sciences, 2021, 22, 8675.	4.1	25
14	Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5979-5992.	7.0	5
15	Cancer-Associated Mutations in Normal Colorectal Mucosa Adjacent to Sporadic Neoplasia. Clinical and Translational Gastroenterology, 2020, 11, e00212.	2.5	3
16	Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma. Oncogenesis, 2020, 9, 59.	4.9	6
17	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Scientific Reports, 2020, 10, 9778.	3.3	5
18	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine, 2019, 45, 139-154.	6.1	36

JOHANNES BETGE

#	Article	IF	CITATIONS
19	Detection of mutational patterns in cellâ€free DNA of colorectal cancer by custom amplicon sequencing. Molecular Oncology, 2019, 13, 1669-1683.	4.6	8
20	MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer. Nature Communications, 2019, 10, 2197.	12.8	126
21	A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). BMC Cancer, 2019, 19, 231.	2.6	19
22	CRISPR/Cas9 for cancer research and therapy. Seminars in Cancer Biology, 2019, 55, 106-119.	9.6	206
23	Multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for second line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) Journal of Clinical Oncology, 2019, 37, TPS174-TPS174.	1.6	1
24	Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 503-507.	0.9	2
25	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. Journal of Clinical Oncology, 2018, 36, 2052-2060.	1.6	26
26	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nature Communications, 2018, 9, 4112.	12.8	55
27	A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/â^' nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). BMC Cancer, 2018, 18, 747.	2.6	24
28	Correlation of BMAL1 expression in colorectal cancer with resistance to anti-VEGFA therapy with bevacizumab Journal of Clinical Oncology, 2018, 36, 705-705.	1.6	0
29	A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso Journal of Clinical Oncology, 2018, 36, e15584-e15584.	1.6	1
30	Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer patients. Modern Pathology, 2017, 30, 897-904.	5.5	33
31	Lymph node retrieval in colorectal cancer: determining factors and prognostic significance. International Journal of Colorectal Disease, 2017, 32, 991-998.	2.2	39
32	Multiple behavioral factors are associated with occurrence of large, flat colorectal polyps. International Journal of Colorectal Disease, 2017, 32, 575-582.	2.2	3
33	Identification of a novel predictive genomic biomarker for response to combination bevacizumab in metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2017, 35, 3580-3580.	1.6	2
34	Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. Oncotarget, 2017, 8, 42949-42961.	1.8	42
35	Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. Oncotarget, 2017, 8, 84714-84728.	1.8	5
36	A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax) Journal of Clinical Oncology, 2017, 35, TPS10124-TPS10124.	1.6	0

JOHANNES BETGE

#	Article	IF	CITATIONS
37	Abstract 5766: High-content microscopy-based screening of colorectal organoids. , 2017, , .		Ο
38	Risk Factors for Local Recurrence of Large, Flat Colorectal Polyps after Endoscopic Mucosal Resection. Digestion, 2016, 93, 311-317.	2.3	26
39	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. Digestion, 2016, 94, 129-137.	2.3	10
40	A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). Annals of Oncology, 2016, 27, vi241.	1.2	0
41	MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 255-265.	2.8	102
42	Frequent co-occurrence of high-grade dysplasia in large flat colonic polyps (>20Âmm) and synchronous polyps. BMC Gastroenterology, 2015, 15, 82.	2.0	10
43	Amplicon Sequencing of Colorectal Cancer: Variant Calling in Frozen and Formalin-Fixed Samples. PLoS ONE, 2015, 10, e0127146.	2.5	34
44	Abstract 967: A novel regulator of Wnt-signaling in colorectal cancer. , 2014, , .		0
45	Is there a rationale to record lymphatic invasion in node-positive colorectal cancer?. Journal of Clinical Pathology, 2012, 65, 847-850.	2.0	2
46	Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer. Annals of Surgical Oncology, 2012, 19, 3706-3712.	1.5	90
47	Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. Cancer, 2012, 118, 2184-2184.	4.1	3
48	Intramural and extramural vascular invasion in colorectal cancer. Cancer, 2012, 118, 628-638.	4.1	204
49	Perineural Invasion Is a Strong and Independent Predictor of Lymph Node Involvement in Colorectal Cancer. Diseases of the Colon and Rectum, 2011, 54, e273.	1.3	4
50	Gastric cancer and concomitant renal cancer: A systematic immunohistochemical and molecular analysis. Oncology Reports, 2011, 26, 567-75.	2.6	6
51	Vascular invasion, perineural invasion, and tumour budding: predictors of outcome in colorectal cancer. Acta Gastro-Enterologica Belgica, 2011, 74, 516-29.	1.0	17
52	Targeting euchromatic histone lysine methyltransferases sensitizes colorectal cancer to histone deacetylase inhibitors. International Journal of Cancer, 0, , .	5.1	2